Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once daily versus placebo for non-alcoholic steatohepatitis
2016-000685-39Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Novo Nordisk. Primary endpoint: NASH resolution without worsening of fibrosis. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-000685-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000685-39.